

CHEMBIO DIAGNOSTICS, INC.
Form 8-K
May 30, 2007

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): May 30, 2007 (May 23, 2007)

CHEMBIO DIAGNOSTIC, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of Incorporation)	0-30379 (Commission File Number)	88-0425691 (IRS Employer Identification Number)
--	---	--

**3661
Horseblock
Road
Medford, NY
11763**

(Address of
principal
executive
offices)

631-924-1135
(Registrant's
Telephone
Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Edgar Filing: CHEMBIO DIAGNOSTICS, INC. - Form 8-K

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01. Regulation FD Disclosures.

On May 23, 2007 the Registrant issued the press release titled “Chembio and Infectious Disease Research Institute Collaborating on Development of Rapid Tests for Leishmaniasis and Leprosy” included herein as Exhibit 99.1.

On May 30, 2007 the Registrant issued the press release titled “Chembio Appoints Robert L. Aromando, Jr. Senior Vice President, Commercial Operations” included herein as Exhibit 99.2.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release titled “Chembio and Infectious Disease Research Institute Collaborating on Development of Rapid Tests for Leishmaniasis and Leprosy” issued May 23, 2007.

99.2 Press Release titled “Chembio Appoints Robert L. Aromando, Jr. Senior Vice President, Commercial Operations” issued May 30, 2007.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing. This Current Report on Form 8-K does not constitute a determination of whether any information included herein is material.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 30, 2007

Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert
Lawrence A. Siebert
Chief Executive Officer